We marginally reduce our estimate by 1-2% for FY22E-23E, due to delay in launch of key molecules (gCopaxone, gVascepa and gNuvaring) along with increased overhead costs, higher freight costs and key clinical trials. DRRD recently received another CRL for gCopaxone, which would delay the launch by 4-6months, while new generic launches in gVescepa (by Hikma) and...